Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2019-07, Vol.381 (4), p.338-348 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 4 |
| container_start_page | 338 |
| container_title | The New England journal of medicine |
| container_volume | 381 |
| creator | Loriot, Yohann Necchi, Andrea Park, Se Hoon Garcia-Donas, Jesus Huddart, Robert Burgess, Earle Fleming, Mark Rezazadeh, Arash Mellado, Begoña Varlamov, Sergey Joshi, Monika Duran, Ignacio Tagawa, Scott T Zakharia, Yousef Zhong, Bob Stuyckens, Kim Santiago-Walker, Ademi De Porre, Peter O’Hagan, Anne Avadhani, Anjali Siefker-Radtke, Arlene O |
| description | Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with
FGFR
alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients. |
| doi_str_mv | 10.1056/NEJMoa1817323 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02930806v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2263410851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-fbe2d7944f52ec01dc4540d317aec517441df27a035225e97c97a2ba609fc5e53</originalsourceid><addsrcrecordid>eNp1kUtLw0AQgBdRtFaPXiUggh6is69sc6ylvqh6sedlutnQLUlWd9OC_96EqqDgXAaGj29ehJxQuKIgs-vn6eOTRzqiijO-QwZUcp4KAdkuGQCwUSpUzg_IYYwr6IKKfJ8ccMoFQC4G5GYaCixd6xq3SFyTzLzBqvpIxsUGG2OLxIfkybYYW2ydSebBt0tbOaySCQbjGl_jEdkrsYr2-CsPyfx2-jq5T2cvdw-T8Sw1kos2LReWFSoXopTMGqCFEVJAwalCayRVQtCiZAqBS8akzZXJFbIFZpCXRlrJh-Ry611ipd-CqzF8aI9O349nuq8ByzmMINvQjr3Ysm_Bv69tbHXtorFVhY3166gZy0TXRfFee_YHXfl1aLpNeooLCiPZC9MtZYKPMdjyZwIKun-E_vWIjj_9sq4XtS1-6O_Ld8D5FqjrqBu7qv8RfQJrlIvV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2263410851</pqid></control><display><type>article</type><title>Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Loriot, Yohann ; Necchi, Andrea ; Park, Se Hoon ; Garcia-Donas, Jesus ; Huddart, Robert ; Burgess, Earle ; Fleming, Mark ; Rezazadeh, Arash ; Mellado, Begoña ; Varlamov, Sergey ; Joshi, Monika ; Duran, Ignacio ; Tagawa, Scott T ; Zakharia, Yousef ; Zhong, Bob ; Stuyckens, Kim ; Santiago-Walker, Ademi ; De Porre, Peter ; O’Hagan, Anne ; Avadhani, Anjali ; Siefker-Radtke, Arlene O</creator><creatorcontrib>Loriot, Yohann ; Necchi, Andrea ; Park, Se Hoon ; Garcia-Donas, Jesus ; Huddart, Robert ; Burgess, Earle ; Fleming, Mark ; Rezazadeh, Arash ; Mellado, Begoña ; Varlamov, Sergey ; Joshi, Monika ; Duran, Ignacio ; Tagawa, Scott T ; Zakharia, Yousef ; Zhong, Bob ; Stuyckens, Kim ; Santiago-Walker, Ademi ; De Porre, Peter ; O’Hagan, Anne ; Avadhani, Anjali ; Siefker-Radtke, Arlene O ; BLC2001 Study Group</creatorcontrib><description>Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with
FGFR
alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1817323</identifier><identifier>PMID: 31340094</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antitumor activity ; Bladder cancer ; Cancer ; Chemotherapy ; Creatinine ; Drug dosages ; Editorials ; Enzyme inhibitors ; Fibroblast growth factor receptor 1 ; Fibroblast growth factor receptors ; Gene expression ; Humans ; Immune clearance ; Immunotherapy ; Kaplan-Meier Estimate ; Kinases ; Life Sciences ; Metastases ; Metastasis ; Middle Aged ; Mutation ; Neoplasm Metastasis - drug therapy ; Pharmaceutical sciences ; Progression-Free Survival ; Protein Kinase Inhibitors - administration & dosage ; Protein-tyrosine kinase ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrazoles - administration & dosage ; Pyrazoles - adverse effects ; Quinoxalines - administration & dosage ; Quinoxalines - adverse effects ; R&D ; Receptors, Fibroblast Growth Factor - antagonists & inhibitors ; Receptors, Fibroblast Growth Factor - genetics ; Research & development ; Response rates ; Survival ; Treatment Outcome ; Urologic Neoplasms - drug therapy ; Urologic Neoplasms - genetics ; Urologic Neoplasms - pathology ; Urothelial carcinoma ; Urothelium]]></subject><ispartof>The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2019 Massachusetts Medical Society.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-fbe2d7944f52ec01dc4540d317aec517441df27a035225e97c97a2ba609fc5e53</citedby><cites>FETCH-LOGICAL-c534t-fbe2d7944f52ec01dc4540d317aec517441df27a035225e97c97a2ba609fc5e53</cites><orcidid>0000-0002-8852-5754</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1817323$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1817323$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31340094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02930806$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Loriot, Yohann</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Park, Se Hoon</creatorcontrib><creatorcontrib>Garcia-Donas, Jesus</creatorcontrib><creatorcontrib>Huddart, Robert</creatorcontrib><creatorcontrib>Burgess, Earle</creatorcontrib><creatorcontrib>Fleming, Mark</creatorcontrib><creatorcontrib>Rezazadeh, Arash</creatorcontrib><creatorcontrib>Mellado, Begoña</creatorcontrib><creatorcontrib>Varlamov, Sergey</creatorcontrib><creatorcontrib>Joshi, Monika</creatorcontrib><creatorcontrib>Duran, Ignacio</creatorcontrib><creatorcontrib>Tagawa, Scott T</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Zhong, Bob</creatorcontrib><creatorcontrib>Stuyckens, Kim</creatorcontrib><creatorcontrib>Santiago-Walker, Ademi</creatorcontrib><creatorcontrib>De Porre, Peter</creatorcontrib><creatorcontrib>O’Hagan, Anne</creatorcontrib><creatorcontrib>Avadhani, Anjali</creatorcontrib><creatorcontrib>Siefker-Radtke, Arlene O</creatorcontrib><creatorcontrib>BLC2001 Study Group</creatorcontrib><title>Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with
FGFR
alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antitumor activity</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Creatinine</subject><subject>Drug dosages</subject><subject>Editorials</subject><subject>Enzyme inhibitors</subject><subject>Fibroblast growth factor receptor 1</subject><subject>Fibroblast growth factor receptors</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Immune clearance</subject><subject>Immunotherapy</subject><subject>Kaplan-Meier Estimate</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Metastasis - drug therapy</subject><subject>Pharmaceutical sciences</subject><subject>Progression-Free Survival</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein-tyrosine kinase</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyrazoles - adverse effects</subject><subject>Quinoxalines - administration & dosage</subject><subject>Quinoxalines - adverse effects</subject><subject>R&D</subject><subject>Receptors, Fibroblast Growth Factor - antagonists & inhibitors</subject><subject>Receptors, Fibroblast Growth Factor - genetics</subject><subject>Research & development</subject><subject>Response rates</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Urologic Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - genetics</subject><subject>Urologic Neoplasms - pathology</subject><subject>Urothelial carcinoma</subject><subject>Urothelium</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kUtLw0AQgBdRtFaPXiUggh6is69sc6ylvqh6sedlutnQLUlWd9OC_96EqqDgXAaGj29ehJxQuKIgs-vn6eOTRzqiijO-QwZUcp4KAdkuGQCwUSpUzg_IYYwr6IKKfJ8ccMoFQC4G5GYaCixd6xq3SFyTzLzBqvpIxsUGG2OLxIfkybYYW2ydSebBt0tbOaySCQbjGl_jEdkrsYr2-CsPyfx2-jq5T2cvdw-T8Sw1kos2LReWFSoXopTMGqCFEVJAwalCayRVQtCiZAqBS8akzZXJFbIFZpCXRlrJh-Ry611ipd-CqzF8aI9O349nuq8ByzmMINvQjr3Ysm_Bv69tbHXtorFVhY3166gZy0TXRfFee_YHXfl1aLpNeooLCiPZC9MtZYKPMdjyZwIKun-E_vWIjj_9sq4XtS1-6O_Ld8D5FqjrqBu7qv8RfQJrlIvV</recordid><startdate>20190725</startdate><enddate>20190725</enddate><creator>Loriot, Yohann</creator><creator>Necchi, Andrea</creator><creator>Park, Se Hoon</creator><creator>Garcia-Donas, Jesus</creator><creator>Huddart, Robert</creator><creator>Burgess, Earle</creator><creator>Fleming, Mark</creator><creator>Rezazadeh, Arash</creator><creator>Mellado, Begoña</creator><creator>Varlamov, Sergey</creator><creator>Joshi, Monika</creator><creator>Duran, Ignacio</creator><creator>Tagawa, Scott T</creator><creator>Zakharia, Yousef</creator><creator>Zhong, Bob</creator><creator>Stuyckens, Kim</creator><creator>Santiago-Walker, Ademi</creator><creator>De Porre, Peter</creator><creator>O’Hagan, Anne</creator><creator>Avadhani, Anjali</creator><creator>Siefker-Radtke, Arlene O</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-8852-5754</orcidid></search><sort><creationdate>20190725</creationdate><title>Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma</title><author>Loriot, Yohann ; Necchi, Andrea ; Park, Se Hoon ; Garcia-Donas, Jesus ; Huddart, Robert ; Burgess, Earle ; Fleming, Mark ; Rezazadeh, Arash ; Mellado, Begoña ; Varlamov, Sergey ; Joshi, Monika ; Duran, Ignacio ; Tagawa, Scott T ; Zakharia, Yousef ; Zhong, Bob ; Stuyckens, Kim ; Santiago-Walker, Ademi ; De Porre, Peter ; O’Hagan, Anne ; Avadhani, Anjali ; Siefker-Radtke, Arlene O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-fbe2d7944f52ec01dc4540d317aec517441df27a035225e97c97a2ba609fc5e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antitumor activity</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Creatinine</topic><topic>Drug dosages</topic><topic>Editorials</topic><topic>Enzyme inhibitors</topic><topic>Fibroblast growth factor receptor 1</topic><topic>Fibroblast growth factor receptors</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Immune clearance</topic><topic>Immunotherapy</topic><topic>Kaplan-Meier Estimate</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Metastasis - drug therapy</topic><topic>Pharmaceutical sciences</topic><topic>Progression-Free Survival</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein-tyrosine kinase</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyrazoles - adverse effects</topic><topic>Quinoxalines - administration & dosage</topic><topic>Quinoxalines - adverse effects</topic><topic>R&D</topic><topic>Receptors, Fibroblast Growth Factor - antagonists & inhibitors</topic><topic>Receptors, Fibroblast Growth Factor - genetics</topic><topic>Research & development</topic><topic>Response rates</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Urologic Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - genetics</topic><topic>Urologic Neoplasms - pathology</topic><topic>Urothelial carcinoma</topic><topic>Urothelium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loriot, Yohann</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Park, Se Hoon</creatorcontrib><creatorcontrib>Garcia-Donas, Jesus</creatorcontrib><creatorcontrib>Huddart, Robert</creatorcontrib><creatorcontrib>Burgess, Earle</creatorcontrib><creatorcontrib>Fleming, Mark</creatorcontrib><creatorcontrib>Rezazadeh, Arash</creatorcontrib><creatorcontrib>Mellado, Begoña</creatorcontrib><creatorcontrib>Varlamov, Sergey</creatorcontrib><creatorcontrib>Joshi, Monika</creatorcontrib><creatorcontrib>Duran, Ignacio</creatorcontrib><creatorcontrib>Tagawa, Scott T</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Zhong, Bob</creatorcontrib><creatorcontrib>Stuyckens, Kim</creatorcontrib><creatorcontrib>Santiago-Walker, Ademi</creatorcontrib><creatorcontrib>De Porre, Peter</creatorcontrib><creatorcontrib>O’Hagan, Anne</creatorcontrib><creatorcontrib>Avadhani, Anjali</creatorcontrib><creatorcontrib>Siefker-Radtke, Arlene O</creatorcontrib><creatorcontrib>BLC2001 Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loriot, Yohann</au><au>Necchi, Andrea</au><au>Park, Se Hoon</au><au>Garcia-Donas, Jesus</au><au>Huddart, Robert</au><au>Burgess, Earle</au><au>Fleming, Mark</au><au>Rezazadeh, Arash</au><au>Mellado, Begoña</au><au>Varlamov, Sergey</au><au>Joshi, Monika</au><au>Duran, Ignacio</au><au>Tagawa, Scott T</au><au>Zakharia, Yousef</au><au>Zhong, Bob</au><au>Stuyckens, Kim</au><au>Santiago-Walker, Ademi</au><au>De Porre, Peter</au><au>O’Hagan, Anne</au><au>Avadhani, Anjali</au><au>Siefker-Radtke, Arlene O</au><aucorp>BLC2001 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2019-07-25</date><risdate>2019</risdate><volume>381</volume><issue>4</issue><spage>338</spage><epage>348</epage><pages>338-348</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><abstract>Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with
FGFR
alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>31340094</pmid><doi>10.1056/NEJMoa1817323</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8852-5754</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348 |
| issn | 0028-4793 1533-4406 1533-4406 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02930806v1 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antitumor activity Bladder cancer Cancer Chemotherapy Creatinine Drug dosages Editorials Enzyme inhibitors Fibroblast growth factor receptor 1 Fibroblast growth factor receptors Gene expression Humans Immune clearance Immunotherapy Kaplan-Meier Estimate Kinases Life Sciences Metastases Metastasis Middle Aged Mutation Neoplasm Metastasis - drug therapy Pharmaceutical sciences Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein-tyrosine kinase Protein-Tyrosine Kinases - antagonists & inhibitors Pyrazoles - administration & dosage Pyrazoles - adverse effects Quinoxalines - administration & dosage Quinoxalines - adverse effects R&D Receptors, Fibroblast Growth Factor - antagonists & inhibitors Receptors, Fibroblast Growth Factor - genetics Research & development Response rates Survival Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - genetics Urologic Neoplasms - pathology Urothelial carcinoma Urothelium |
| title | Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erdafitinib%20in%20Locally%20Advanced%20or%20Metastatic%20Urothelial%20Carcinoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Loriot,%20Yohann&rft.aucorp=BLC2001%20Study%20Group&rft.date=2019-07-25&rft.volume=381&rft.issue=4&rft.spage=338&rft.epage=348&rft.pages=338-348&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1817323&rft_dat=%3Cproquest_hal_p%3E2263410851%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2263410851&rft_id=info:pmid/31340094&rfr_iscdi=true |